<DOC>
	<DOCNO>NCT02215044</DOCNO>
	<brief_summary>Determination maximum tolerate dose ( MTD ) , safety , tolerability BI 2536 give Day 1 Day 15 combination gemcitabine give Day 1 , Day 8 Day 15 every 28 day patient locally advance metastatic pancreatic adenocarcinoma characterisation antitumor activity , pharmacokinetic ( PK ) profile , CA 19-9 tumor marker response response combination BI 2536 gemcitabine patient locally advance metastatic pancreatic adenocarcinoma .</brief_summary>
	<brief_title>Dose-finding Study BI 2536 Administered Combination With Gemcitabine Patients With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patient histologically cytologically confirm locally advanced , unresectable metastasize adenocarcinoma pancreas : 1. receive gemcitabine chemotherapy locally advance metastatic pancreatic cancer 2. progressive disease least 6 month cessation adjuvant gemcitabine chemotherapy follow curative surgical tumor resection Male female patient age 18 year old Life expectancy least three ( 3 ) month Eastern Cooperative Oncology Group ( ECOG ) performance score 2 less Patient must give write informed consent Prior chemo ( adjuvant gemcitabine ) , hormone ( Megace® ) immunotherapy Ampullary carcinoma pancreas Brain metastasis , symptomatic require therapy Patients lifethreatening illness organ system dysfunction , opinion investigator , would either compromise patient safety interfere evaluation safety test drug Other malignancy diagnose within past five ( 5 ) year ( nonmelanomatous skin cancer ) Absolute neutrophil count ( ANC ) &lt; 1,500/μl , platelet count &lt; 150,000/μl , hemoglobin &lt; 9 g/dl Total bilirubin &gt; 1.8mg/dl ( &gt; 30.78 μmol/l , , international system unit ( SI ) equivalent ) adequate drainage measure ( case obstructive jaundice ) No hepatic metastasis : Aspartate amino transferase ( AST ) and/or alanine amino transferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) . Hepatic metastasis : aspartate amino transferase ( AST ) and/or alanine amino transferase ( ALT ) &gt; 5 x ULN Serum creatinine &gt; 2.0 mg/dl ( &gt; 176 μmol/L , SI Unit equivalent ) Radiotherapy within last 2 week prior treatment trial drug Patients serious active infection ( i.e. , require IV antibiotic , antifungal , antiviral agent ) Patients know HIV , HepatitisB C infection Known suspect active drug alcohol abuse Women childbearing potential ; men able father child unwilling use medically acceptable method contraception trial Pregnancy breast feeding Treatment investigational drug within past 4 week within less four halflife time investigational drug treatment trial drug and/or persistence toxicity prior anticancer therapy deem clinically relevant Patient unable comply protocol Patients require warfarin ( Coumadin® ) patient know preexist coagulopathy unrelated pancreatic cancer ( This mean , example , patient long ( year ) history recurrent venocclusive disease clearly precede diagnosis pancreatic cancer exclude study . Patients recent hypercoagulable state ( ie deep vein thrombosis pulmonary embolism ) due pancreatic cancer clinically stable low molecular weight heparin exclude ) Patients neuropathy ( sensory motor ) ≥ common terminology criterion adverse event ( CTCAE ) 3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>